Exosomes and Extracellular Vesicles

Introduction to Extracellular Vesicles

Extracellular vesicles (EVs) are membrane-bound nano-scale particles secreted by essentially all cell types, containing a cargo of proteins, lipids, nucleic acids (miRNAs, mRNAs, DNA), and metabolites that can be transferred to recipient cells locally or at a distance—mediating intercellular communication without direct cell-cell contact. EV research has exploded since the mid-2000s when small secreted vesicles were shown to carry functional mRNA and miRNA transferred between cells; the 2013 Nobel Prize in Physiology or Medicine to James Rothman, Randy Schekman, and Thomas Sudhof (vesicle trafficking) provided context for the mechanistic biology underpinning EV biogenesis and secretion.

EVs are classified by size and biogenesis mechanism: exosomes (30-150 nm, intraluminal vesicles of multivesicular bodies (MVBs) released by MVB fusion with plasma membrane—with ESCRT and ceramide pathways directing cargo sorting); microvesicles (100-1000 nm, direct plasma membrane budding); apoptotic bodies (500-5000 nm, released during apoptosis containing fragmented nuclear components). The 2018 ISEV Minimal Information for Studies of Extracellular Vesicles (MISEV) guidelines standardised EV characterisation requirements: particle size distribution (NTA, cryo-EM, DLS), protein markers (CD63, CD9, CD81 for exosome-enriched fractions; TSG101, Alix for MVB origin) and negative markers (Golgi, ER markers indicating non-exosomal contamination), and concentration quantification.

EV Biogenesis and Cargo Sorting

ESCRT Pathway

The ESCRT (Endosomal Sorting Complex Required for Transport) machinery sorts ubiquitinated membrane proteins and cytoplasmic cargo into intraluminal vesicles (ILVs) of MVBs. The four ESCRT complexes (0, I, II, III) act sequentially: ESCRT-0 (Hrs, STAM) clusters cargo; ESCRT-I (TSG101, VPS28) selects cargo; ESCRT-II initiates membrane invagination; ESCRT-III (charged multivesicular body proteins, CHMPs) drives membrane fission; VPS4 AAA-ATPase disassembles the complex. TSG101 is widely used as an exosome marker. Cargo proteins with specific ubiquitin patterns, tetraspanin interactions (CD63, CD81 directing cargo to exosomes), ESCRT-independent ceramide pathway (sphingomyelinase activity generating ceramide-enriched microdomains favouring ILV formation), and HSP90/HSC70 chaperone interactions determine whether proteins are sorted into ILVs or degraded.

miRNA Sorting in Exosomes

miRNA sorting to exosomes involves sequence-specific mechanisms—certain miRNAs are preferentially enriched in EVs over source cells, indicating active sorting versus passive RNA loading. HNRNPA2B1 recognises GGAG motifs in miRNAs, shuttling them to exosomes. MEX3C ubiquitin E3 ligase associates with specific miRNA sequences. Ceramide pathway generates MVB ILVs specifically enriched for certain miRNA families. Sumoylated hnRNPA2B1 modifies miRNA loading in a stress-responsive manner. Exosomal miRNAs delivered to recipient cells can function as gene-regulatory signals: miR-21 from tumour-derived EVs modulates recipient cell behaviour; immune cell-derived EVs delivering miR-155 influence inflammation; cardiac progenitor cell exosomal miRNAs reduce cardiomyocyte apoptosis after myocardial infarction in animal models.

EVs in Disease

Tumour-Derived EVs

Cancer cells secrete abundant EVs carrying oncoproteins, immune modulatory cargo, and metastasis-promoting signals. Tumour EVs prepare the pre-metastatic niche—EVs from pancreatic cancer expressing integrin alphavbeta5 preferentially bind fibronectin in liver, recruiting bone marrow-derived macrophages and inducing inflammatory gene expression creating a hospitable liver microenvironment for subsequent metastatic seeding. Tumour EVs deliver PD-L1 to distant lymph nodes and circulation suppressing CD8 T cell activation systemically. GBM EVs deliver EGFR mutation to neighbouring non-malignant cells inducing transformation-associated transcriptional changes. Tumour EV biogenesis is driven by hypoxia, YAP/TAZ activity, and Rab27a/b regulating MVB trafficking to plasma membrane for secretion.

EVs in Immune Signalling

Dendritic cell (DC) exosomes carry MHC-peptide complexes enabling antigen presentation to T cells without direct DC contact—amplifying adaptive immune initiation. DC-derived exosomes in clinical trials as cancer vaccines present tumour antigen peptides on MHC class II and class I stimulating CD4 and CD8 T cells. Macrophage polarisation signals are carried by EVs: M1 macrophage EVs carry inflammatory miRNAs (miR-223, miR-155); M2 EVs carry anti-inflammatory cargo modulating recipient macrophage polarisation—relevant in chronic inflammation and tumour immune microenvironment. B cell exosomes carry complement receptors enabling opsonised antigen presentation; platelet-derived EVs activate coagulation and promote cancer metastasis by transferring adhesion molecules and growth factors.

EVs as Therapeutics and Drug Delivery

EVs are being engineered as drug delivery vehicles leveraging their native cell-targeting tropism, cell membrane crossing ability, and reduced immunogenicity compared to liposomes. Exosomes from macrophages cross the blood-brain barrier—used to deliver siRNA, miRNA, or chemotherapy to brain tumours in mouse models. Mesenchymal stem cell (MSC)-derived EVs have paracrine regenerative effects in myocardial infarction, liver fibrosis, and renal injury models—potentially mediating the beneficial effects of MSC transplantation through secreted EVs rather than engraftment. Engineering strategies: surface modification with targeting peptides (Lamp2b fused to neuron-targeting RVG peptide for brain targeting), electroporation of therapeutic nucleic acids, or genetic loading through overexpression in EV-producing cells.

Examples and Applications

Example 1: Liquid Biopsy Using EV-Derived cfDNA

Tumour EVs release cell-free DNA (cfDNA) including circulating tumour DNA (ctDNA) carrying cancer-specific somatic mutations into blood—forming the basis of liquid biopsy cancer diagnostics. ctDNA from EV fractions is enriched for certain cancer-derived sequences and provides specific somatic mutation information (KRAS, EGFR, TP53) enabling minimally invasive tumour genotyping for treatment selection, monitoring of treatment response, and early detection of resistance mutations before radiological progression. Plasma EV miRNA profiles correlate with tumour type and stage—multi-miRNA classifiers (ExoDx, ExoIntelligence, Exosome Diagnostics panels) are in development for prostate cancer and lung cancer diagnosis from urine or blood respectively. EV protein cargo (EpCAM, CD147, PD-L1 on EVs) provides additional cancer-specific biomarker dimensions.

Example 2: Cardiac Exosomes in Cardioprotection

Cardiac progenitor cells (CPCs) protect cardiomyocytes from ischaemia-reperfusion injury through paracrine mechanisms; exosome fraction of CPC conditioned medium reproduced protective effects in equivalent models. CPC exosomal cargo includes miR-210 (reducing mitochondrial dysfunction), miR-132 (reducing oxidative stress), and heat shock proteins with anti-apoptotic functions. In porcine MI models, intracoronary injection of CPC exosomes reduced infarct size and improved cardiac function. Phase I clinical trials delivering MSC exosomes or CPC exosomes after acute MI and chronic heart failure enrolled patients based on this preclinical evidence. The challenge of translating rodent/porcine EV studies to clinical efficacy requires standardising production, dosing, and delivery—and demonstrating mechanism and target engagement in patients.

Example 3: EV Isolation Methods

EV isolation is technically challenging—different methods yield different EV populations with different purity and yield. Differential ultracentrifugation (dUC): 300g (remove cells), 2000g (remove cell debris), 10,000g (sediment microvesicles), 100,000g (pellet exosomes)—most common but co-pelleting protein aggregates reduces purity. Density gradient UC on sucrose or iodixanol gradients separates EVs by density (1.09-1.18 g/mL for exosomes) improving purity. Size exclusion chromatography (SEC, qEV columns) separates by size with good preservation of EV integrity. Polymer precipitation (PEG-based ExoQuick)—rapid, scalable but low purity. Immunoprecipitation with anti-tetraspanin beads (CD63, CD9) provides high specificity for exosome-enriched fractions. Asymmetric flow field-flow fractionation (AF4) enables high-resolution continuous size fractionation separating exosomes from small aggregates and other nanoparticles.

Example 4: Milk Exosomes and Immune Education

Breast milk contains abundant exosomes and other EVs—among the highest EV concentrations in any biological fluid—carrying immunological, hormonal, and growth-regulatory cargo. Milk EVs carry miRNAs (including immune-regulatory miR-155, miR-148a, miR-146b) that are bioavailable in neonate, modulating neonatal immune development. Cow's milk EVs survive pasteurisation (~50% activity retained) and oral administration, raising the possibility that dietary EVs communicate nutritional status and regulate recipient gene expression. Milk EV CD8 regulatory T cell-inducing cargo may contribute to the protective effect of breastfeeding against allergic disease and autoimmunity. Bovine milk EVs loaded with exogenous nucleic acids (paclitaxel mRNA, curcumin) are being investigated as oral drug delivery vehicles exploiting their GI stability and cellular uptake efficiency.

Example 5: EV-Mediated Prion-Like Spread

Misfolded protein aggregates (prions, tauopathy tau, alpha-synuclein in Parkinson's, TDP-43 in ALS) propagate between cells in a prion-like 'seed and amplify' pattern—EVs are implicated in intercellular transfer of these pathological protein seeds. Tau-containing exosomes isolated from brains of tauopathy patients seed tau aggregation in healthy neurons after injection into mouse brain—establishing spread competency of brain EV-associated tau. Alpha-synuclein is detectable in blood and CSF EVs from Parkinson's patients; EV-associated alpha-synuclein propagation may explain the Braak staging model of Parkinson's pathology progressing from gut/olfactory bulb caudally. EV-mediated pathological spread is also implicated in ALS (SOD1, TDP-43 aggregates) and Huntington's disease, making EV biogenesis pathway inhibition a potential neuroprotective therapeutic strategy.

Example 6: EVs in Coagulation and Thrombosis

Platelet-derived microparticles (PMPs, 100-1000 nm) are released during platelet activation—they are the most abundant EVs in blood (~100 million per mL). PMPs express phosphatidylserine (PS) on their outer leaflet—the essential cofactor for pro-thrombinase complex assembly generating thrombin. PMPs also carry P-selectin, GPIb, GPIIb/IIIa enabling additional platelet-interaction amplification and VWF-mediated capture at injury sites. Elevated PMP concentrations correlate with thrombotic risk in antiphospholipid syndrome, atherosclerosis, and cancer. Cancer-derived EVs activate platelets and coagulation—contributing to Trousseau's syndrome (cancer-associated thrombosis) through EV tissue factor exposure. EV PS quantification in clinical samples is being developed as a coagulation biomarker for thrombosis risk stratification.

Example 7: EV Communication in the Tumour Microenvironment

EVs extensively remodel the tumour microenvironment (TME). Tumour EVs: educate macrophages toward M2 pro-tumour phenotype through IL-10, TGF-beta EV cargo; transfer drug resistance to sensitive tumour cells by delivering multidrug resistance proteins (P-glycoprotein, BCRP) via EV membrane transfer; promote angiogenesis by delivering VEGF, miR-9, and miR-130a to endothelial cells. Tumour EVs convert cancer-associated fibroblasts (CAFs) to more pro-tumour myofibroblast phenotype through TGF-beta and Wnt EV cargo. Conversely, fibroblast EVs can paradoxically suppress tumour growth through anti-tumour miRNA delivery. EVs from natural killer cells carrying perforin and granzymes can directly kill cancer cells—NK cell EV-based therapy is in early development as a cell-free tumouricidal approach.

Example 8: Engineered EVs for Drug Delivery

Engineering EVs as drug delivery vectors involves passive and active cargo loading strategies. Electroporation of exosomes loads siRNA or miRNA into the EV lumen but causes aggregation reducing EV yield/quality—sonication and incubation-based loading preserve EV integrity better. Three primary engineering approaches: (1) pre-loading in EV producer cells by overexpressing therapeutic cargo with EV sorting signals (CD63 fusion proteins, Lamp2b miRNA cargo); (2) surface decoration of isolated EVs with targeting ligands using click chemistry or EDC-NHS conjugation; (3) hybrid engineering creating liposome-EV chimera with improved scalability and reproducibility. Exosome-mimics produced by cell membrane extrusion create scalable EV-like nanoparticles from 100x more cells under equivalent conditions. Clinical-grade EV manufacturing under GMP conditions is a critical bottleneck requiring standardisation for therapeutic applications.

Try it live

Everything above runs in your browser — open Exosomes and Extracellular Vesicles and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.